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Questionnaires play a key place in the assessment of asthma control. Different questionnaires
have been developed. However, it remains largely unknown whether they can be used inter-
changeably. We wondered whether the panel of frequently used scores would give similar mea-
surement of asthma control. The present study aimed to assess the agreement between five
specific questionnaires.
Methods: In this prospective study, ninety-nine patients completed five commonly used
asthma control scores: the GINA, the Asthma Control Test, the Royal College of Physician
score, the Asthma Therapy Assessment Questionnaire (ATAQ), and the Asthma Control Ques-
tionnaireª (ACQ). The kappa coefficient was used to assess the agreement between question-
naires.
Results: The agreement between the GINA and other scores was only moderate (kappa coeffi-
cients amounted from 0.41 to 0.60). With respect to the “controlled” level, all the other scores
gave higher results than GINA. All other scores also tended to underestimate GINA “uncon-
trolled level”. For the “partly controlled level” defined by 3 of the 5 questionnaires, ACQ iden-
tified the same percentage of patients than GINA while ATAQ overestimated this percentage.
Conclusion: This study shows only moderate agreement between five commonly used asthma
control scores. The GINA score showed the lowest percentage of controlled and the highestress: Division of Pulmonary Diseases, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4,
: þ41 22 79 553 34 49.
hoo.com (F. Vermeulen), marianne.paesmans@bordet.be (M. Paesmans), Inge_Muylle@stpierre-bru.
re-bru.be (M. Bruyneel), Vincent_Ninane@stpierre-bru.be (V. Ninane).
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Asthma control measurement: A prospective study 1315percentage of uncontrolled asthma. As a consequence, all these scores do not seem to eval-
uate the same symptoms.
Trial Registration number: NCT01350661.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Asthma control was defined as the extent to which the
various manifestations of asthma have been reduced or
removed by treatment [1]. This evaluation has taken a key
place in the management of asthma. Indeed, recommen-
dations emphasize the importance of asthma control eval-
uation to guide the adaptation of drug therapy [2] and this
is mainly performed using various composites scores.
Whether these scores are categorical or continuous, pre-
dicted values have been proposed to define two or three
levels of control. Although several scores have been pub-
lished [2e10], they differ by the factors that were consid-
ered and the weight that was given to each item [1]. They
are mainly used according to local preference for the
everyday management of asthma but are also the pillar of
asthma assessment in many studies on asthma treatment or
monitoring modalities.
A limited number of studies have assessed the level of
agreement of the different available scores [11e14] and
suggest that these scores are not interchangeable. These
studies however have limitations related to the fact that
they generally compare only two different scores between
them, most often taking the GINA score as the comparator
and to the fact that they were performed retrospectively
using data from prospective studies that included strictly
selected population. In addition, only two studies [14,15]
have used the kappa coefficient to accurately assess the
interobserver agreement between these questionnaires.
We wondered whether the panel of frequently used scores
would give similar measurement of asthma control in a
prospective study with asthma patients. With this in mind,
we have assessed control of asthma in all consecutive pa-
tients referred to our outpatient asthma clinic during a one
year period using five frequently used questionnaires,
namely the GINA score [2], the Asthma Control Test (ACT)
[3], the Asthma Control Questionnaireª (ACQ) [4], the
Asthma Therapy Assessment Questionnaire (ATAQ) [5] and,
the Royal College of Physician score (RCP) [6].Figure 1 Flowchart diagram. (FeNO: fraction of exhaled ni-
tric oxide; GINA: Global initiative for asthma [2]; ACT: Asthma
control test [3]; ACQ: Asthma control questionnaire [4]; ATAQ:
Asthma therapy assessment questionnaire [5]; RCP: Royal col-
lege of physicians [6]).Methods and material
Patients
This prospective observational study was performed in the
outpatient’s clinic of asthma from the University hospital
Saint-Pierre, Brussels, Belgium. During a one-year period
(June 2010eJune 2011), the principal investigator proposed
to each consecutive asthma patient coming for a routine
visit to participate. The only prerequisite was a diagnosis of
asthma and an age older than 18 and younger than 70 years.
The diagnosis of asthma included a clinical history ofasthma for at least 3 months. Patients also had to demon-
strate a FEV1 reversibility exceeding 12% of the absolute
value and 200 mL in response to inhalation of a short-acting
beta 2-agonist.Methods
After having signed an informed consent, each patient was
asked to complete successively in a random order, the
following five asthma control scores: GINA score [2], ACT
[3], ACQ [4], ATAQ [5], and the RCP [6] (Fig. 1). For each
patient, a randomization table created in MS Excel (Micro-
soft, Redmond, USA) determined the order of the ques-
tionnaires. The principal investigator could give
clarifications to the patient during questionnaire comple-
tion. The GINA questionnaire includes a question about the
occurrence of exacerbation in the last year. The principal
investigator questioned the patient on exacerbation
1316 F. Vermeulen et al.occurrence during the last year and, if possible, confirmed
timing by analysis of medical records.
On the same day, a spirometry was performed using the
Jaeger Masterscreen Pneumo (CareFusion Corp., San Diego,
USA), as well as measurement of fractional exhaled nitric
oxide (FeNO), using the Niox Flex (Aerocrine AB, Solna,
Sweden). Patients were blinded with respect to the results
of spirometry and exhaled NO until the total completion of
scores. The study has been approved by the Institutional
Ethics Committee of CHU Saint-Pierre.
Questionnaires
The main characteristics of the five questionnaires are
summarized in Table 1.
The GINA questionnaire includes six questions about
symptoms, the forced expiratory volume in one second
(FEV1), and the occurrence of exacerbation. If an exacer-
bation occurred in the last week, the patient is considered
to be uncontrolled, whatever the other results. According
to GINA guidelines, an exacerbation is defined as an acute
and severe loss of control that requires urgent treatment.
This questionnaire is proposed by experts and has not been
any validated.
The ACT includes five questions related to symptoms,
reliever use, and self-rating of the level of asthma control.
To answer, a Likert-scale from 1 to 5 is proposed. Results of
each question are summed and validation has been reached
according to the following: a score 19 was defined as
characterizing a not controlled asthma. This value was
determined because it corresponds to the best sensitivity
and specificity (respectively 71.3% and 78.2%) when
comparing overall agreement between ACT and specialist’s
rating of patient’s level of control. Validation of reliability
was performed using the Cronbach’s alpha coefficients
calculated for the entire sample of patients, for the group
of “not controlled” patients and for the group ofTable 1 Characteristics of 5 asthma control scores. (NA: not av
G
Recall time, week(s) 1
n items 6
n levels of control 3
Minimal important difference N
Subjective items
Daytime symptoms B
Shortness of breath
Wheezing
Usual symptoms
Nighttime symptoms B
Symptoms at wake up in the morning
Nighttime symptoms and at wake up in the morning
Limitation of activities B
Self-assessment
Semi-objective items
Reliever use B
Objective items
Lung function B
Exacerbation B“controlled” patients with good results (respectively 0.84,
0.83, and 0.79) [3].
The RCP score is the result of a consensus (without
further validation) issued from a multidisciplinary seminar
organized by the Royal College of Physicians (UK) in 1998
[6]. It includes three questions related to nocturnal symp-
toms, diurnal symptoms, and limitation of activity. For each
item, two answers are possible: yes or no. Each “yes”
answer counts as 1 point. A score 1 means that the asthma
is not controlled.
The ACQ and encompasses questions about symptoms,
use of reliever, and lung function [4]. Results of the seven
questions are averaged to obtain the final score. In order to
determine the level of control, two cut-off values have
been described [15]. A score 0.75 means that asthma is
controlled, whereas a score 1.5 means that asthma is
uncontrolled. A minimal clinical important difference value
of 0.5 was also determined [16]. The process of validation,
applied to 50 patients followed during 9 weeks, has shown
that the ACQ has good longitudinal validity (intraclass cor-
relation coefficient in the stable group about 0.90) and
responsiveness to change in asthma control (p < 0.0001)
[4].
The ATAQ is a four questions score that assesses limita-
tion of activity, nocturnal awakening, self-assessment of
asthma control level, and reliever use [5]. Possible answers
include “yes”, “no” or “uncertain”. It should be noted that
the answer “uncertain” counts for one point in favour of
the level “not controlled”. In addition, if the patient takes
less than 5 “reliever” puffs/day, the value is 0 in favour of
“controlled” asthma. No validation process was applied.
Analysis
Three possible levels of asthma control were considered,
namely“controlled”, “partly controlled”or“not controlled”.
The agreement was assessed using the kappa coefficient [17]ailable; B: Quantitative items; C: Qualitative items).
INA ACT ACQ ATAQ RCP
4 1 4 1 (4)
5 7 4 3
2 3 3 2
A NA 0.5 NA NA
B B
B
B
B B B
C
B
B B B B
C C
B B B
B
Asthma control measurement: A prospective study 1317calculated using Statistical Package for Social Sciences 19
(IBM; Chicago, USA). As all scores do not have the same
number of asthma control levels (two or three), the partly
controlled and uncontrolled levels were combined when
calculating the Kappa coefficient. As kappa coefficient only
allows comparing two scores between them, the GINA score
was initially compared to the four other scores and the
remaining side-by-side comparisons were made thereafter.
All kappa values were characterized according to the
nomenclature proposed by Landis and Koch [18]. They sug-
gested arbitrary words to describe the importance of agree-
ment between observers (<0.00 poor; 0.00e0.20 slight;
0.21e0.40 fair; 0.41e0.60 moderate; 0.61e0.80 substantial;
0.81e1.00 almost perfect). The KruskaleWallis test was used
to compare the scores of each level of control respectively. A
p value < 0.05 was considered as significant.
As no data allowed us to generate hypotheses about
score distributions and/or differences between scores, this
study was considered as exploratory and analysis was
mainly descriptive. Therefore, we did not carry out a priori
sample size estimation but we chose to include a maximumTable 2 Characteristics of included patients according to GI
beclomethasone diproprionate equivalent. (FEV1: Forced expirat
oxide; BMI: body mass index; ICS: inhaled corticosteroids; GERD
agonist; LABA: long-acting b2-agonist; LTRA: leukotriene receptor
GINA classification
Controlled Pa
n 28 21
Sex F/1M 3.0 1.
Age yrs 43.8  14.5 39
Body mass index kg/m2 26.9  6.1 27
Time from diagnosis yrs 9.85  16.4 6.
FEV1 L 2.88  0.74 3.
FEV1% of predicted value 97  12 10
FeNO ppb 34.1  33.3 31
Comorbidities
Smoking 2 (7.1%) 2
GERD 9 (32.1%) 11
Chronic rhinosinusitis 15 (53.5%) 11
Sleep apnoea syndrome 2 (7.1%) 1
Obesity (BMI > 30) 6 (21.4%) 4
Allergies 22 (78.5%) 17
ICS dose prescribed
No ICS 4 (14.2%) 4
<400 mcg 10 (35.7%) 3
400e799 mcg 7 (25.0) 6
>799 mcg 7 (25%) 8
Medical treatment
No treatment 2 (7.1%) 1
SABA 18 (64.3%) 17
LABA 0 (0.0%) 1
ICS 7 (25.0%) 6
ICS þ LABA 17 (60.7%) 12
Theophyline 0 (0.0%) 1
LTRA 7 (25%) 7
OCS 0 (0.0%) 0
Anti-IgE 1 (3.6%) 0number of patients in a reasonably short time period (one
year accrual).Results
During the 12 months period, 105 patients were invited to
participate in the study. Ninety-nine were included. Six
patients refused to participate because they reported lack
of time to fill out questionnaires. The characteristics of
included patients, classified according to the GINA control
levels, are presented in Table 2. Uncontrolled asthma was
not associated with differences in anthropometric charac-
teristics and frequency of comorbidities but with signifi-
cantly lower FEV1 and a tendency toward increased doses of
inhaled corticosteroids. No difference in FeNO measure-
ments was observed.
The agreement between the GINA score, on one side and
the ATAQ, the ACT, RCP and the ACQ, on the other side was
moderate with kappa coefficient observed values that
amounted to 0.49, 0.41, 0.52 and 0.60 respectively (Table 3).NA score of asthma control. ICS dosages are expressed in
ory volume in one second; FeNO: fraction of exhaled nitric
: gastro-oesophageal reflux disease; SABA: short-acting b2-
antagonist; OCS: oral corticosteroids: IgE: immunoglobulin E).
p
rtly controlled Uncontrolled
50
6 1.6 0.614
.3  19.0 43.1  17.2 0.501
.0  7.7 26.9  6.0 0.945
3  6.3 11.7  14.0 0.101
13  0.68 2.47  0.87 0.002
0  12 80  19 <0.001
.6  24.8 38.9  33.4 0.566
(9.5%) 10 (20.0%) 0.237
(52.3%) 17 (34.0%) 0.277
(52.3%) 26 (52.0%) 0.991
(4.7%) 2 (4.0%) 0.831
(19.0%) 16 (32.0%) 0.420
(80.9%) 35 (70.0%) 0.541
(19.0%) 7 (14.0%) 0.855
(14.3%) 8 (16.0%) 0.179
(28.6%) 9 (18.0%) 0.464
(38.1%) 26 (52%) 0.065
(4.8%) 3 (6%) 0.737
(81%) 38(76%) 0.209
(4.8%) 1 (2.0%) 0.252
(28.6%) 13 (26.0%) 0.785
(57.1%) 37 (74%) 0.806
(4.8%) 0 (0.0%) NA
(33.3%) 13 (26%) 0.533
(0.0%) 5 (10.0) NA
(0.0%) 1 (2.0%) 0.678
Table 3 Kappa values issued from comparison of pairs of
scores.
GINA ACQ ACT ATAQ
ACQ 0.60 e e e
ACT 0.41 0.58 e e
ATAQ 0.49 0.37 0.62 e
RCP 0.52 0.57 0.53 0.58
1318 F. Vermeulen et al.The ACQ and ATAQ had the worse agreement with a
kappa value of 0.37. On the other hand, ACQ and respec-
tively RCP and ACT had only a moderate agreement
(respective kappa values of 0.57 and 0.58). ACT and RCP as
well as ATAQ and RCP had also a moderate agreement
(respective kappa value of 0.53 and 0.58). The best
agreement was observed between ACT and ATAQ with a
kappa value of 0.62.
Fig. 1 shows a graphical view of the comparison between
the GINA score and the ACQ, ACT, RCP and ATAQ results.
With respect to the “controlled” level, all scores gave
higher results than GINA (ACQ þ12.1%, ATAQ þ16.2%, ACT
þ21.2%, RCP þ4.0%). For the “partly controlled level” ACQ
identified the same percentage of patients than GINA while
ATAQ overestimated this percentage (þ15.2%). Concerning
the “uncontrolled” level of control, all scores under-
estimated the GINA result (ACQ 12.1%, ATAQ 31.3%, ACT
21.2%, RCP 4.0%). Fig. 2 shows a similar graphical view
of the different side-by-side comparisons between the
ACQ, ACT, RCP and ATAQ and comparisons of results showed
significant differences between ACT and RCP (p < 0.001),
ACQ and ATAQ (pZ 0.002), ACT and ATAQ (pZ 0.025), and
ACQ and ACT (p Z 0.049). No significant difference was
observed between ATAQ and RCP (p Z 0.067) or between
ACQ and RCP (p Z 0.074).
Comparisons of the percentage of patients in different
levels of control (Table 4) also showed a statisticallyFigure 2 Percentage of patients identified by each score for each
score. For ACT and RCP, with only two levels of control, the GINA ‘
and expressed as GINA2 in the figure.significant difference between GINA and respectively ACQ,
ATAQ and ACT scores (p < 0.001) but not with the RCP score
(p Z 0.374). Differences were, however, often important.
As an example, for the level “controlled”, this percentage
ranged from 4.0 to 21.2%, for the level “partly controlled”
from 0.0 to 15.2%, and for the level “uncontrolled” from 4.0
to 31.3%.Discussion
In the present study, the level of agreement between five
commonly used scores of asthma control was assessed
prospectively in a population of ambulatory asthma pa-
tients. The results show an only moderate overall agree-
ment between them. In addition, for each given level of
asthma control, the proportion of patients varies according
to the scores. All together, these results suggest that these
questionnaires are not interchangeable.
Previous studies have already compared questionnaires
between them. Koolen et al. [11] studied the ability of ACT
to identify patients with uncontrolled asthma in comparison
with GINA score. They found that ACT with a cut-off value
19 shows a sensitivity of 66% and a specificity of 100% and
then suggested to increase the ACT cut-off value in order to
increase sensitivity. Alvarez-Gutie´rrez et al. [12] also
compared ACT and GINA scores and noticed that the ACT,
for each GINA levels of control, classified only 59.4, 54.1 and
63.6% of the patients correctly. It is noteworthy that they
proposed an additional, second cut-off for the ACT, such
that it would include three levels of control. Finally, Thomas
et al. [13] assessed the relationship between RCP and ACQ,
and its course over 12 weeks. Despite the relatively small
sample and a single cut-off to 1.0 for the ACQ, they
observed a strong relationship (0.79, p < 0.001) between
these scores. However, even though the RCP identified 94%
of poor controlled episodes, the authors observed that 35%
of the cases were considered as “controlled” using the ACQ.level of control. GINA (solid line) is considered as the reference
partly controlled’ level was included in the ‘uncontrolled one’
Figure 3 Relative values of each level of control for each
score. (White, solid line: controlled asthma; Grey: partly
controlled asthma; Black: uncontrolled asthma; White, dotted
line: impact in percentage of the total score of one single
unitary change in answer to question).
Table 4 Percentage of patients identified for each level
of asthma control using the 5 questionnaires. The partly and
uncontrolled values of GINA are summed to be compared to
the ACT and RCP that have only two possible categories
(controlled or uncontrolled).
GINA ACQ ACT ATAQ RCP
Controlled 28.3 40.4 49.5 44.4 32.3
Partly controlled 21.2 71.7 21.2 e 36.4 e
Uncontrolled 50.5 38.4 50.5 19.2 67.7
Asthma control measurement: A prospective study 1319Consequently, they suggested that RCP may over-estimate
inadequate control. Altogether, these studies already sug-
gested that these questionnaires are not interchangeable.
Their limitations, however, are related to the fact that they
were most often retrospective, comparing a limited number
of questionnaires, in a selected population of asthma pa-
tients and often without kappa coefficient analysis.
Indeed, the classical statistical test designed to assess
the interobserver agreement is the kappa coefficient [17]
that gives a value between 0 and 1. A value of 1 indicates
the perfect agreement whereas, on the opposite, a value of
0 means that agreement is equivalent to chance. To date,
only two studies assessed the agreement between scores
using this coefficient. Thomas et al. [19] retrospectively
compared the ACT and GINA results in more than 2900 pa-
tients and found a kappa coefficient of 0.42. They observed
that a value of ACT 19 is a good predictor of partly
controlled/uncontrolled level, according to GINA since this
cut-off identified 93.9% of patients. However, this per-
centage only amounted to 51.3% when controlled patients
were considered. More recently, O’Byrne et al. [14] made a
post hoc analysis of three studies comparing three scales,
GINA, ACQ-5 (a shorter validated version of the ACQ) and
the Gaining Optimal Asthma Control (GOAL) index [10].
They indeed found that GINA and GOAL have a substantial
agreement with a kappa of 0.80 but this was not the case
between GINA and ACQ since kappa value was only 0.61
when comparing GINA uncontrolled level and ACQ-5 1.5.
These previous observations as well as our results
showing moderate agreement between five frequently used
scores can be explained by different causes. The first one is
related to differences in properties and validation. Indeed,
few questionnaires meet all described quality criteria to
assess the measurement properties of health status ques-
tionnaires [20e22]. Interestingly, the GINA score, which
could be considered as a reference, has not been formally
validated. This is also the case for the RCP. As far as ATAQ is
concerned, authors showed good correlations between
ATAQ, quality of life, and health care utilization but no
formal validation was published [5]. Only the ACQ and ACT
have been fully validated [3,4]. A second potential expla-
nation is linked to the content of scores. Most of the time
when creating a score, an initial set of items submitted to a
panel of experts is gradually reduced and finally validated.
Experts can also directly propose items in a final version.
Even if expert opinion can be considered as valid at first
sight, it is interesting to note that only one item (limitation
of activity) is found in each of the five questionnaires
(Table 1). A third explanation is related to accuracy of
questionnaires. Indeed, the number of questions includedin each score and the number of possible answers for each
question vary according to questionnaires. This implies that
the change of a single response will influence the final
outcome to a different extent in different scores (Fig. 3).
For example, changing an answer in the RCP modifies the
final result by an amount that is equal to about one third.
On the other hand, the change of a single answer in the
ACQ, changes the final result by only 2.4%. A fourth reason
is related to differences in the timing of recall: GINA and
ACQ require a recall time of 7 days. In contrast, for the ACT
and ATAQ, the patient should remember the last four
weeks. RCP is less clear because it accounts for the last
week or last month. These two periods are typically used,
although their choice seems to be based on relatively
empirical data [1,23]. In addition, it has been shown that
the severity of symptoms at the time of completing a
questionnaire affects the perception that one can have
from the same symptoms appeared a few days earlier [24].
A last reason is specific to the GINA questionnaire. This was
the only one to assess previous exacerbations. The occur-
rence of an exacerbation during the last week determines
an uncontrolled asthma independently of the results to
other questions. One may expect that this would explain
the higher incidence of uncontrolled asthma using this
questionnaire. In the present study, 8 patients have had an
exacerbation during the week before the inclusion. This
corresponds to 16.0% of uncontrolled patients according to
GINA. As a comparison, for the four other questionnaires,
the number of patients exacerbated in the last week and
the percentage of uncontrolled patients according to each
questionnaire was 6 (12.0%) for the ACT, 6 (15.8%) for the
ACQ, 5 (26.3%) for the ATAQ, and 8 (11.9%) for the RCP.
All together, these factors may partly explain the vari-
ability of agreements between questionnaires observed in
the present study.
This study also shows some potential limitations. At first,
the number of included patients may seem low in com-
parison with the large number of patients from retrospec-
tive studies [14,19]. However, these ones comparing pairs
of questionnaires (GINA vs ACQ [14], GINA vs ACT [19])
observed kappa values identical to those of the present
study, a finding which suggests that the sample size of our
study is likely to be large enough.
1320 F. Vermeulen et al.In the present study, a reference questionnaire was
required for the pertinence and comparison of Kappa
analysis. No questionnaire had clear advantages over the
others and the GINA questionnaire was then selected on the
reason that GINA guidelines are the most frequently and
globally used guidelines for the management of asthma. We
believe however that the selection of another reference
would not have affected the general conclusion of the
present study.
Questions included in the different questionnaires are
often similar and are also part of the regular questions that
are asked by clinicians outside questionnaire use to assess
asthma. We do not believe that this may induce any limi-
tation and it must be stressed that none of the patients
from the present study had to complete any of these
structured questionnaires before and the order of ques-
tionnaire administration was randomized.
Additional scores could also have been included in our
study. The GOAL index [10] was not considered as it in-
volves filling a daily diary with symptoms and PEF values
during the whole week before the assessment. Given the
fact that other scores do not provide this diary, we decided
to not include GOAL. Boulet et al. [9] proposed a score that
included assessment of symptoms, FEV1, and sputum
eosinophilia. Despite its usefulness [25], induced sputum is
currently not routinely used and this led us not to take into
account this score in the present analysis.
RCP and ACT scores provide only 2 categories, namely
“controlled” or “not controlled” state. In order to compare
both these scores with other three scores, we decided to
combine the categories “partly controlled” and “uncon-
trolled”. This has however the disadvantage of masking
patients who are “partially controlled” such that the
calculated kappa values relate only the “controlled” cate-
gory. Radar charts (Fig. 1) let show the distribution of pa-
tients for each level of control.
Since these questionnaires do not seem to be inter-
changeable, one may ask which one is the most convenient
for research purpose and conversely for clinical use. The
present data do not allow making quantitative assessment
but some information can be retrieved from the question-
naire characteristics. The ACQ seems, at first sight, to be
the best questionnaire for research purpose since it has
been validated, includes minimal clinically important dif-
ference, has high accuracy as illustrated in Fig. 3 and also
shows additional information related to FEV1 measurement.
For clinical use, ACT also shows high accuracy and has the
advantage that FEV1 measurement is not required. The
three other questionnaires all show some significant flaw:
none of them are validated, their accuracy is less good
(Fig. 3) and GINA if used for clinical practice requires in
addition FEV1 measurement.
In conclusion, this prospective study including patients
with a wide range of levels of asthma control shows a
moderate agreement between five commonly used scores
of asthma control. These results demonstrate that these
scores are not interchangeable. Cautious is then required
when achieving literature reviews or meta-analyzes that
include studies assessing the level of asthma control. In the
clinical setting, the present findings also suggest that the
same score should be used and repeated in a given patient
in order to allow longitudinal follow-up and comparison.COI disclosure
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